Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blinded, Comparative Trial Comparing the Incidence of Hypophosphatemia in Relation to Repeated Treatment Courses of Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease

Next Previous
Trial Profile

A Randomized, Double-blinded, Comparative Trial Comparing the Incidence of Hypophosphatemia in Relation to Repeated Treatment Courses of Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ferric derisomaltose (Primary) ; Ferric carboxymaltose
  • Indications Iron deficiency anaemia
  • Focus Adverse reactions
  • Acronyms PHOSPHARE-IBD
  • Sponsors Pharmacosmos

    • Most Recent Events

    • 13 Dec 2022 Results of post hoc analysis exploring the effects of ferric derisomaltose (FDI) vs. ferric carboxymaltose (FCM), on fatigue as a patient-reported outcome, presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 18 May 2022 Results assessing health state utility values (HSUVs) from a recent randomized controlled trial (PHOSPHARE-IBD; NCT03466983) of intravenous iron in the treatment of patients with IBD and IDA, presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 18 Feb 2021 Status changed from recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top